HEALTH PEI VALUES Caring We treat everyone with compassion, respect, fairness, and dignity Integrity We collaborate in an environment of trust, communicate with openness and honesty, and are accountable through responsible decision-making Excellence We pursue continuous quality improvement through innovation, integration, and the adoption of evidence-based practices
WHY DOES URINE MATTER TO YOU?
Introduce yourself to your colleagues and share…..
Objectives: - HOW DID WE GET HERE? - LIAISON PROGRAM - CADTH PRODUCTS - EVIDENCE INFORMED DECISIONS - URINE MATTERS #URINE MATTERS- TWITTER
CADTH is a health technology assessment
agency
We inform technology-related decision-making
in health care
How did we get here?
CADTH’S VISION
HEALTH TECHNOLOGY ASSESSMENT INFORMS EVERY HEALTH TECHNOLOGY DECISION.
CADTH’S MISSION TO ENHANCE THE HEALTH OF CANADIANS BY PROMOTING THE OPTIMAL USE OF HEALTH TECHNOLOGIES.
KNOWLEDGE SHARING: A CADTH SERVICE
Evidence Informed Decision Making
.
Commonly Requested Products The following table provides brief descriptions of the products CADTH most commonly produces in response to requests, as well as approximate completion times.
Product Type Description* Approximate turnaround time from point of topic refinement**
Reference list List of the best available evidence with abstracts and links to full-text documents, if available.
5 to 10 business days
Summary of abstracts Summary based on the abstracts of the best available evidence. Includes the abstracts and
links to full-text documents, if available.
15 business days
Summary with critical appraisal Written summary of the evidence from full text
articles, with a critical appraisal and policy implications.
30 business days
Peer-reviewed summary with critical appraisal
Summary of systematically selected evidence with a critical appraisal and policy implications. An
external peer-review is conducted.
Four months
Systematic review and meta-
analysis
A systematic review of the evidence and a meta-
analysis is performed, where appropriate. Authorship includes a content expert, and an
external peer-review is conducted.
4 to 5 months
Rapid health technology
assessment
A systematic review of clinical studies and an
economic component that includes a systematic
review of economic studies, an economic evaluation or a budget impact analysis. It excludes
a review of the health services impact. Authorship includes a content expert, and an external peer-
review is conducted.
5 to 6 months
Environmental Scan Scan of innovative technologies or pan-Canadian
access, reimbursement, or practice issues.
5 to 40 business days
Drug review and formulary
recommendation
Rigorous review of the clinical and cost-
effectiveness of a drug, and a formulary listing recommendation for Canada’s publicly funded
drug plans (excluding Quebec) through CADTH’s Common Drug Review process. Typically,
submissions are received from drug manufacturers; however, the CDR-participating
drug plans may also request a CDR review.
5 to 6 months
Health technology assessment Comprehensive, evidence-based analysis of a
health technology or technologies to support and inform decisions about health policy, purchasing,
service management, and clinical practice. May
include a systematic review of clinical evidence, a systematic review of cost-effectiveness, and
information on the broader impact on patient health and the health care system.
Determined on a case-by-case basis
Optimal use project Project designed to encourage the optimal use of a health technology or technologies by health care
providers, policy-makers, and consumers. May include a systematic review of clinical evidence, a
systematic review of cost-effectiveness, and development of recommendations, supporting
documents, and tools.
Determined on a case-by-case basis
*These products may be tailored to meet the needs and timelines of the requestor and are subject to the
quality and quantity of the published literature.
**The turnaround times are subject to the capacity and ongoing projects at CADTH. Timelines will be
negotiated between a CADTH representative and the requestor at the time of topic refinement.
RAPID RESPONSE • DRUGS
• DIAGNOSTICS
• DEVICES
• SURGICAL AND MEDICAL PROCEDURES
Collaboration.
PARTNERSHIPS REQUIRED.
CADTH ROADSHOW. PANCANADIAN PERSPECTIVES
LAB UTILIZATION-A CADTH ROADSHOW
SAVE THE DATE! Sharing the results.
March 23, 2015 National Webinar
Urine Matters.
UTI CARE PATHWAYS FOR ENHANCED COLLABORATION & ANTIBIOTIC SAFETY IN SENIORS.
Interior Slide
Contributing to the conversation about laboratory test optimization and encouraging it to continue.
What does the evidence say?
Clinical and Cost Effectiveness 1. What is the clinical effectiveness of urine cultures
and sensitivity analysis, urine dipstick testing, or urinalysis for urine testing in asymptomatic residents in long term-care?
2. What is the cost effectiveness of urine cultures and sensitivity analysis, urine dipstick testing, or urinalysis for urine testing in asymptomatic residents in long-term care?
20
Evidence-based Guidelines 3. What are the evidence-based guidelines regarding
the ordering of urine cultures and sensitivity tests, dipstick tests, and urinalysis for residents in long-term care?
4. What are the evidence-based guidelines regarding proper collection of urine for urine testing in long-term care residents?
5. What are the evidence-based guidelines regarding the interpretation of urine test results?
21
WHAT DOES THE EVIDENCE SAY?
6. What is the clinical evidence on the development of antibiotic resistance to norfloxaxin in treatment of urinary tract infections (UTIs)?
7. What is the clinical evidence regarding the
safety of nitrfurantoin in elderly males with urinary tract infections?
What does the evidence say?
8.What is the comparative clinical effectiveness of long-term antibiotic prophylaxis and treatment of urinary tract infections (UTIs) in the elderly?
9.What are the evidence-based guidelines
regarding the management of UTIs with antibiotics in the elderly?